EpiLAB

Tuberculosis is a devastating pandemic, the disease claimes 1,5 million victims each year. According to the WHO, in 2020, 10 million people fell ill with tuberculosis among which 3 million are not diagnosed . These cases are extremely contagious and lead to 10 million infections the following year. These 3 million patients are untreated and half of them die from the disease. 
The main reason for this under-diagnosis is the lack of appropriate testing in developing countries, where 90% of cases are located : every available tests require medical infrastructure and qualifications, while those countries are lacking of both.

EpiLAB is addressing this problem by developing the first portable and easy to use tuberculosis diagnosis test. To do so, EpiLAB leverages a patented tuberculosis detection method using specific enzymatic reactions coupled with electrochemical detection. This technology is low cost, operates on battery and could be deployed by individuals without any medicine qualification. Essentially, our goal is to elaborate a pristine screening kit for tuberculosis.

EpiLAB is supported by French and world renowned tuberculosis expert. The WHO has also confirmed the great interest for EpiLAB test, and many NGOs and National Program to fight TB have sent letters of interest to EpiLAB.

EpiLAB is closing a 500k€ round to complete its R&D and will be looking for 5M€ next year to start industrial production.